Business Context and Reporting Period
Company: BiomX Inc. (PHGE)
Reporting Period: Quarter and six months ended June 30, 2026
Strategic Pivot: The Company has transitioned from a clinical-stage biopharmaceutical business to a defense, security, and critical infrastructure technology firm. This shift followed the discontinuation of its Phase 2b clinical trial in late 2025 and the commencement of insolvency proceedings for its former Israeli subsidiary, BiomX Ltd. (deconsolidated February 4, 2026).
Key Acquisitions: In April 2026, the Company acquired 100% of ZorroNet Ltd. (AI-powered security) and a 60% controlling interest in Dr. Frucht Systems Ltd. (DFSL) (LADAR-based detection systems).
Key Financial Metrics
| Metric (USD in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenues | 332 | - |
| Gross Profit | 97 | - |
| Operating Loss | (6,710) | (15,189) |
| Net Loss | (22,986) | (13,696) |
| Net Loss Attributable to Stockholders | (22,912) | (13,696) |
| Cash and Cash Equivalents (End of Period) | 347 | 14,046 |
| Total Assets | 28,186 | 5,783 |
| Total Liabilities | 10,563 | 7,085 |
| Stockholders' Equity | 17,623 | (1,302) |
Note: The 2026 Net Loss includes significant non-cash charges related to warrant fair value adjustments and Day 1 losses on financing transactions.
Material Changes vs. Prior Period
- Revenue Generation: The Company recorded $332,000 in revenue for the first time in the six months ended June 30, 2026, derived from the newly acquired defense subsidiaries (DFSL and ZorroNet). No revenue was recorded in the comparable 2025 period.
- Operating Expenses: Operating loss decreased significantly from $15.2 million to $6.7 million. This improvement was driven by the deconsolidation of BiomX Ltd. and the cessation of clinical trial expenses ($7.0 million reduction in R&D), partially offset by increased General and Administrative (G&A) expenses due to stock-based compensation and insurance.
- Non-Cash Charges: The Net Loss increased primarily due to a $12.5 million loss from the change in fair value of liability-classified warrants and a $5.2 million "Day 1 loss" upon entering the January 2026 private placement transaction.
- Balance Sheet: Total assets increased to $28.2 million, largely due to the recognition of $25.4 million in Goodwill and Intangible Assets from the April 2026 acquisitions. Cash reserves declined from $4.4 million to $0.3 million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern. Current funds are projected to be sufficient for only the "next several months." The Company relies on future capital raises, ATM sales, and revenue from new subsidiaries to fund operations.
- Unusual Items:
- Deconsolidation Gain: Recognized a $1.9 million gain from the deconsolidation of BiomX Ltd. following the appointment of a trustee in insolvency proceedings.
- Warrant Volatility: Significant volatility in the fair value of liability-classified warrants issued in the January 2026 private placement drove a large portion of the reported net loss.
- Listing Compliance: The Company is not in compliance with NYSE American stockholders' equity standards. A compliance plan has been accepted with a deadline of September 25, 2027. Failure to regain compliance could result in delisting.
- Legal Proceedings:
- BiomX Ltd. Insolvency: A trustee has been appointed; the Company owes approximately $1.3 million to the subsidiary, which may be subject to creditor claims.
- Adaptive Phage Therapeutics (APT): APT is a defendant in a lawsuit seeking ~$333,000 and is expected to file for Chapter 7 bankruptcy shortly.
- Outlook: The Company expects to continue incurring losses while integrating new subsidiaries. Future liquidity depends on the success of the At-The-Market (ATM) program and the ability to raise additional capital.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $347,000 cash balance against projected operating expenses for the next 3-6 months.
- Stockholder Approval: Confirm the outcome of the special meeting scheduled for August 25, 2026, regarding the issuance of shares for the DFSL acquisition and Mandragola credit facility (required to avoid dilution limits).
- Listing Status: Monitor progress on the NYSE American compliance plan to avoid delisting.
- Debt Obligations: Review the repayment schedule for the $1.25 million promissory note to Water IO (extended to November 2026) and the status of the $2.0 million Mandragola credit line.
- Non-Cash Losses: Assess the impact of recurring fair value adjustments on warrant liabilities on future earnings reports.